Eli Lilly and Company thrives on its groundbreaking weight-loss drug tirzepatide. Learn why we could see a $50B market and ...

Eli Lilly recently acquired a smaller biotech for its promising investigational pain medication. The company generates strong ...

The global weight-loss drug market is experiencing exceptional growth, projected to expand from around $144.6 billion in 2023 ...

Eli Lilly is a pharma player, but it offers the growth of a tech stock thanks to its weight loss drugs portfolio. The weight ...

Financial Stability: Eli Lilly's balance sheet is more robust, with debt making up only 4% of equity, considerably less than ...

Although as of this week the stock has declined by more than 4% since the start of the year, there's little reason to believe ...

Eli Lilly's stock boomed April 17 after announcing a ... the company's "mission to reduce chronic diseases like type 2 diabetes," which it says is expected to roughly impact 760 million adults ...

Eli Lilly & Co.’s stock soared 14% Thursday ... results from a late-stage trial of a GLP-1 treatment for Type 2 diabetes and obesity in pill form. The last time the stock rose as much was ...

The success of Eli Lilly & Co. 's weight-loss and diabetes drugs has pushed the company's stock to new heights, helping the founding family's endowment become the largest private foundation in the U.S ...